Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
PurposeImmunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
The huKS-IL2 immunocytokine (IC) consists of IL2 fused to a mAb against EpCAM, while the hu14.18-IL2 IC recognizes the GD2… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore… Expand
Is this relevant?
Review
2009
Review
2009
Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
BackgroundTo explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2004
2004
Established s.c. NXS2 murine neuroblastoma tumors exhibited transient resolution after suboptimal therapy using the hu14.18-IL2… Expand
Is this relevant?
2003
2003
We evaluated recurrent NXS2 neuroblastoma tumors that developed following NK- or T-cell–mediated immunotherapy in tumor-bearing… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?